Premium
Analyse moléculaire de la résistance de Plasmodium falciparum aux antimalariques en Chine
Author(s) -
Zhang G. Q.,
Guan Y. Y.,
Zheng B.,
Wu S.,
Tang L. H.
Publication year - 2009
Publication title -
tropical medicine and international health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.056
H-Index - 114
eISSN - 1365-3156
pISSN - 1360-2276
DOI - 10.1111/j.1365-3156.2009.02342.x
Subject(s) - plasmodium falciparum , malaria , drug resistance , china , virology , protozoal disease , biology , medicine , traditional medicine , geography , immunology , microbiology and biotechnology , archaeology
Summary Objective In China, Chloroquine (CQ) and sulfadoxine–pyrimethamine (SP) were abandoned for the treatment of falciparum malaria 20 years ago due to resistance. Subsequent field studies showed a trend of declining CQ and SP resistance in the country. The main purpose of this study was to analyse the molecular markers of antimalarial resistance and thereby to assess the possibility of reintroduction of CQ or SP for falciparum malaria treatment. Methods Plasmodium falciparum field isolates were collected in 2006–2007 from Hainan and Yunnan provinces, China. Nested PCR‐sequencing assays were applied to analyse the SNPs in four genes: P. falciparum chloroquine resistance transporter ( pfcrt ) gene, multi‐drug resistance 1 ( pfmdr1 ) gene, dihydrofolate reductase ( dhfr ) gene and dihydropteroate synthetase ( dhps ) gene. Results We found the widespread presence of point mutations in the dhfr and dhps genes which are associated with SP treatment failure. The molecular analyses also showed the fairly high prevalence of point mutation in the pfcrt gene which is linked to CQ resistance. Conclusion The results of the present study indicate that CQ and SP should not be reintroduced for falciparum malaria treatment in the near future in China.